| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 435.35 | 7.9% | 26.1% |
| Total Income | 435.35 | 7.9% | 26.1% |
| Expenditure | 404.70 | 6.2% | 16.2% |
| PBT | 27.46 | 39.0% | 562.3% |
| Net Profit | 23.61 | 65.8% | 723.0% |
| OPM | 7.04% | 1.52pp | 7.90pp |
| NPM | 5.42% | 1.89pp | 6.52pp |
| EPS | — |
LifeStance Reports Strong Q2 2026 Results, Raises Full Year Outlook, Announces $100M Share Repurchase Program
06 Aug 2026 · 6 Aug, 3:40 pm
Summary
LifeStance Health Group, Inc. reported strong financial results for the second quarter ended June 30, 2026, with revenue increasing 26% year-over-year to $435.4 million. The company achieved positive net income of $23.6 million, a substantial turnaround from a net loss in the prior year, and saw Adjusted EBITDA grow by 94% to $66.0 million. Management highlighted the strong performance as a result of increased visit volumes and improved operational leverage, leading them to raise the full-year 2026 financial outlook for revenue, Center Margin, and Adjusted EBITDA.
Key Highlights
- 1
Revenue for the second quarter of 2026 reached $435.4 million, marking a 26% increase compared to the prior year's second quarter.
- 2
The company reported a net income of $23.6 million for Q2 2026, a significant improvement from a net loss of $3.8 million in the same period last year.
- 3
Adjusted EBITDA surged by 94% to $66.0 million in Q2 2026, compared to $34.0 million in Q2 2025.
- 4
Center Margin grew by 41% year-over-year to $153.0 million in the second quarter of 2026.
- 5
LifeStance is raising its full-year 2026 outlook for revenue to $1.685 billion - $1.725 billion, Center Margin to $570 million - $594 million, and Adjusted EBITDA to $215 million - $235 million.
- 6
The company's clinician base expanded by 11% year-over-year to 8,542 clinicians, with a sequential net increase of 193 in the second quarter.
- 7
Visit volumes increased by 19% to 2.6 million in the second quarter of 2026.
Management Comments
Dave Bourdon
This was an outstanding second quarter and first half of 2026 for LifeStance, as we delivered quarterly revenue growth of 26%, positive net income of $24 million, and Adjusted EBITDA margins of 15%. This momentum underscores the substantial growth opportunity ahead as we extend our reach into new geographies, broaden our specialty capabilities, and strengthen our differentiation through clinical excellence and measurable patient outcomes.
Informational and educational content only. Not investment advice.